Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Hofheinz, Ralf-Dieter [VerfasserIn]   i
 Ronellenfitsch, Ulrich [VerfasserIn]   i
Titel:Treatment with antiangiogenic drugs in multiple lines in patients with metastatic colorectal cancer
Titelzusatz:meta-analysis of randomized trials
Verf.angabe:R.-D. Hofheinz, U. Ronellenfitsch, S. Kubicka, A. Falcone, I. Burkholder, and U.T. Hacker
Jahr:2016
Umfang:9 S.
Fussnoten:Gesehen am 06.02.2019
Titel Quelle:Enthalten in: Gastroenterology research and practice
Ort Quelle:New York, NY : Hindawi, 2008
Jahr Quelle:2016
Band/Heft Quelle:(2016) Artikel-Nummer 9189483, 9 Seiten
ISSN Quelle:1687-630X
Abstract:Background. In metastatic colorectal cancer (mCRC), continuing antiangiogenic drugs beyond progression might provide clinical benefit. We synthesized the available evidence in a meta-analysis. Patients and Methods. We conducted a meta-analysis of studies investigating the use of antiangiogenic drugs beyond progression. Eligible studies were randomized phase II/III trials. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints were the impact of continuing antiangiogenic drugs (i) in subgroups, (ii) in different types of compounds targeting the VEGF-axis (monoclonal antibodies versus tyrosine kinase inhibitors), and (iii) on remission rates and prevention of progression. Results. Eight studies (3,668 patients) were included. Continuing antiangiogenic treatment beyond progression significantly improved PFS (HR 0.64; 95%-CI, 0.55-0.75) and OS (HR 0.83; 95%-CI, 0.76-0.89). PFS was significantly improved in all subgroups with comparable HR. OS was improved in all subgroups stratified by age, gender, and ECOG status. The rate of patients achieving at least stable disease was improved with an OR of 2.25 (95%-CI, 1.41-3.58). Conclusions. This analysis shows a significant PFS and OS benefit as well as a benefit regarding disease stabilization when using antiangiogenic drugs beyond progression in mCRC. Future studies should focus on the optimal sequence of administering antiangiogenic drugs.
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: http://dx.doi.org/undefined
 Volltext: https://www.hindawi.com/journals/grp/2016/9189483/
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1587334917
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68355778   QR-Code
zum Seitenanfang